Contact Dermatitis
25
2
3
15
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.0%
1 terminated out of 25 trials
93.8%
+7.2% vs benchmark
8%
2 trials in Phase 3/4
33%
5 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (25)
Methotrexat to Hand Eczema in the BIOSKIN Cohort
Novel Skin Barrier Product Versus Petrolatum for Skin Barrier Dysfunction
DermAI to Evaluate Human Factor of Testing
A Clinical Evaluation of Marula-Derived Ceramide Cream on Skin Barrier Function Enhancement
Assessment of Niacinamide Cosmetic Product Efficacy in Model of Irritant Contact Dermatitis
Testing an Intervention in Irritative Contact Dermatitis
Molecular Diagnosis of Allergic Contact Dermatitis
Study on Hypoallergenic Hair Dye
Clinical Evaluation of Lyral® Dose Response Study
Children With Aluminium Contact Allergy: Oral Exposure Study
Children With Aluminium Contact Allergy: Cutaneous Exposure Study
A Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB
Linking Epidermal Barrier Function With Anti-Oxidant Defense Mechanisms in Skin Conditions
Prevention of Dermatitis in Epoxy Exposed Workers
Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study
Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy
Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response
A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers
Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis
Molecular and Cellular Characterization of Spongiotic Dermatitis